Competing Risks in Early Breast Cancer
Author Information
Author(s): R. Arriagada, L.E. Rutqvist, A. Kramar, H. Johansson
Primary Institution: Institut Gustave-Roussy
Hypothesis
The study aims to evaluate the causes of treatment failure and their contribution to the total failure rate in early breast cancer.
Conclusion
The competing risk method provides a more accurate analysis of event-free survival in early breast cancer compared to conventional methods.
Supporting Evidence
- The rate of new primary malignancies was significantly higher in postmenopausal patients (6% vs 3% at 10 years).
- In low-risk, node-negative postmenopausal patients, the incidence of recurrences from breast cancer was no greater than other types of events.
- The competing risk method avoids biases related to assumptions of independence between different types of events.
Takeaway
This study looks at why some breast cancer treatments don't work and finds a better way to measure how long patients stay cancer-free.
Methodology
The study analyzed event-free survival using a competing risk approach in 2,850 patients with early breast cancer, comparing results with conventional methods.
Potential Biases
There may be biases related to the assumptions of independence between different types of events.
Limitations
The study may not account for all potential confounding factors affecting event rates.
Participant Demographics
Patients included pre- and postmenopausal women aged under 71 years with operable breast cancer.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website